DS3610
/ Daiichi Sankyo
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
November 29, 2025
A Study of DS3610a in Participants With Advanced Solid Tumor
(clinicaltrials.gov)
- P1 | N=70 | Recruiting | Sponsor: Daiichi Sankyo | Not yet recruiting ➔ Recruiting
Enrollment open • First-in-human • Solid Tumor
November 10, 2025
DS3610 Enters Clinical Development in Patients with Advanced Solid Tumors as First STING Agonist ADC in Industry-Leading ADC Portfolio of Daiichi Sankyo
(Businesswire)
- "The first patient has been dosed in a first-in-human phase 1 trial evaluating DS3610 in patients with advanced, metastatic or unresectable solid tumors."
First-in-human • P1 data • Solid Tumor
October 31, 2025
DS-3610: Initiation of P1 trial (NCT07159126) for solid tumors in H2 FY2025
(Daiichi Sankyo)
- Q2 FY2025 Results
Trial initiation date • Oncology • Solid Tumor
September 09, 2025
A Study of DS3610a in Participants With Advanced Solid Tumor
(clinicaltrials.gov)
- P1 | N=70 | Not yet recruiting | Sponsor: Daiichi Sankyo
New P1 trial • Solid Tumor
1 to 4
Of
4
Go to page
1